LOGIN  |  REGISTER

Insmed (NASDAQ: INSM) Stock Quote

Last Trade: US$25.27 1.16 4.81
Volume: 2,022,522
5-Day Change: -5.78%
YTD Change: -18.46%
Market Cap: US$3.750B

Latest News From Insmed

BRIDGEWATER, N.J. , April 5, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to seven new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each... Read More
Additional Data from ARISE Study Evaluating the Impact of ARIKAYCE on Microbiologic Outcomes in Patients with Newly Diagnosed or Recurrent MAC Lung Disease to be Presented as Late-Breaker Data to be Presented from ARISE Examining Change in Patient-Reported Respiratory Symptoms BRIDGEWATER, N.J. , March 27, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform... Read More
BRIDGEWATER, N.J. , March 5, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 24 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each... Read More
BRIDGEWATER, N.J. , Feb. 29, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor conferences: The TD Cowen 44 th Annual Health Care Conference in Boston on Monday, March 4, 2024 , at 2:50 p.m. ET in a fireside chat The Leerink Partners... Read More
New survey reveals the prevalence of "Unseenism," which can be described as a social phenomenon where gender and age biases can leave some patients feeling overlooked or unheard, in healthcare 58% of women who chose not to speak up during a visit with their doctor said it was because their health concerns were previously ignored Insmed's educational initiative "Speak Up in BE" aims to bring hope, education, and a sense of... Read More
Topline Data from the Phase 3 ASPEN Trial of Brensocatib in Adult Patients with Bronchiectasis Remain on Track to Read Out in the Latter Part of Second-Quarter 2024 Enrollment in the Phase 2 Study of TPIP in Patients with PH-ILD Completed in November 2023 ; Topline Data Expected in Second-Quarter 2024 Ahead of the ASPEN Readout Company Ends 2023 With $780 Million of Cash, Cash Equivalents, and Marketable Securities,... Read More
BRIDGEWATER, N.J. , Feb. 8, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its fourth-quarter and full year 2023 financial results on Thursday, February 22, 2024 . Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Thursday,... Read More
BRIDGEWATER, N.J. , Feb. 2, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 24 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each... Read More
ARIKAYCE ® (amikacin liposome inhalation suspension) Delivers Full-Year 2023 Revenues Exceeding the Upper End of Guidance Range with Unaudited Global Net Product Sales of Approximately $305.2 Million 2024 Global ARIKAYCE Revenues Expected to be Between $340 Million and $360 Million , Reflecting Double-Digit Growth Compared to 2023 Topline Data from the Phase 3 ASPEN Study of Brensocatib in Adult Patients with Bronchiectasis... Read More
BRIDGEWATER, N.J. , Jan. 4, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 10 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each... Read More
BRIDGEWATER, N.J. , Jan. 2, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the 42 nd Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 8, 2024 , at 3:00 p.m. PT / 6:00 p.m. ET . The presentation and question and answer session... Read More
BRIDGEWATER, N.J. , Dec. 5, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 14 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each... Read More
BRIDGEWATER, N.J. , Nov. 29, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the Nasdaq 49 th Investor Conference in London on Wednesday, December 6, 2023 , at 8:30 a.m. ET / 1:30 p.m. GMT . The fireside chat will be webcast live and can be accessed by... Read More
BRIDGEWATER, N.J. , Nov. 8, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor conferences: The Stifel 2023 Healthcare Conference in New York on Tuesday, November 14, 2023 , at 8:00 a.m. ET in a fireside chat The 6 th Annual Evercore ISI... Read More
BRIDGEWATER, N.J. , Nov. 3, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 21 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each... Read More
Company-wide day of service brings more than 700 employees together to volunteer in 25 locations throughout the U.S., Europe , and Japan BRIDGEWATER, N.J. , Nov. 2, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today holds its second annual Global Day of Good, with hundreds of Insmed employees... Read More
Insmed Leads Science Top Employers List for Third Consecutive Year BRIDGEWATER, N.J. , Oct. 26, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it has earned the highest ranking in Science 's 2023 Top Employers Survey. The annual survey polls employees in biotechnology,... Read More
ARIKAYCE ® (amikacin liposome inhalation suspension) Total Revenue of $79.1 Million for the Third Quarter of 2023 Reflects Highest Quarter of Sales Since Launch and 17% Growth Compared to the Third Quarter of 2022 Company Reiterates Full-Year 2023 Guidance Range for Global ARIKAYCE Revenues of $295 Million to $305 Million Insmed Shares Encouraging Blended and Blinded Dose Titration and Safety and Tolerability Data from the... Read More
BRIDGEWATER, N.J. , Oct. 24, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company, today announced a collaboration with Google Cloud to transform the drug discovery, development, and commercialization landscape of the life sciences industry through the use of generative AI. This alliance will harness the power of Google Cloud's cutting-edge AI technology and Insmed's expertise in... Read More
BRIDGEWATER, N.J. , Oct. 12, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its third-quarter 2023 financial results on Thursday, October 26, 2023 . Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Thursday, October 26, 2023 ,... Read More
BRIDGEWATER, N.J. , Oct. 6, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 16 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each... Read More
BRIDGEWATER, N.J. , Sept. 26, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at Chardan's 7 th Annual Genetic Medicines Conference in New York , on Tuesday, October 3, 2023 at 2:00 p.m. ET . The fireside chat will be webcast live and can... Read More
BRIDGEWATER, N.J. , Sept. 8, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 13 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each... Read More
BRIDGEWATER, N.J. , Sept. 6, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the Morgan Stanley 21 st Annual Global Healthcare Conference in New York , on Monday, September 11, 2023 at 2:55 p.m. ET . The fireside chat will be webcast live... Read More
QOL-B Respiratory Domain Shown to Work Effectively as Patient-Reported Outcome Tool in Patients with MAC Lung Disease; to be Proposed to FDA as Primary Endpoint in ENCORE with No Modifications Patients Treated with ARIKAYCE Plus Macrolide-Based Background Regimen Had Meaningfully Larger Improvements in QOL-B Respiratory Score with Strong Trend Toward Significance vs. Macrolide-Based Background Regimen Alone ARIKAYCE-Treated... Read More
BRIDGEWATER, N.J. , Aug. 4, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 46 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each... Read More
ARIKAYCE ® (amikacin liposome inhalation suspension) Total Revenue of $77.2 Million for the Second Quarter of 2023 Reflects Highest Quarter of Sales Since Launch and 18% Growth Compared to the Second Quarter of 2022 Company Raises Full-Year 2023 Guidance Range for Global ARIKAYCE Revenues to $295 Million to $305 Million Topline Data from Post-Marketing ARISE Study of ARIKAYCE Expected in September of 2023 Blended Blinded... Read More
BRIDGEWATER, N.J. , July 20, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its second-quarter 2023 financial results on Thursday, August 3, 2023 . Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Thursday, August 3, 2023 , to... Read More
BRIDGEWATER, N.J. , July 7, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 10 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each... Read More
BRIDGEWATER, N.J. , June 7, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the Goldman Sachs 44 th Annual Global Healthcare Conference in Dana Point, CA , on Wednesday, June 14, 2023 at 1:20 p.m. PT ( 4:20 p.m. ET ). The fireside chat... Read More
BRIDGEWATER, N.J. , June 6, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 34 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each... Read More
Brensocatib Reduced Risk of Exacerbations Irrespective of Disease Severity in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE) in Phase 2 WILLOW Subgroup Analysis Real-World Cohort Study Shows Fewer Hospitalizations Among Patients with Chronic Obstructive Pulmonary Disease (COPD) Who Received Early Diagnosis of Nontuberculous Mycobacterial (NTM) Lung Disease vs. Patients in the Late-Diagnosis Group Analysis of WILLOW... Read More
Early-Stage Research Pillar Anticipated to Generate at Least Six Investigational New Drug (IND) Applications by End of 2025 Company Reveals Select Initial Disease Targets for Next-Generation Gene Therapies and Deimmunized Therapeutic Proteins, Including Duchenne Muscular Dystrophy (DMD) and Stargardt Disease Gene Therapy Clinical Trial in DMD to be Initiated in 2023, with Data Expected First Half of 2024 Company Announces... Read More
BRIDGEWATER, N.J. , May 5, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 18 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each... Read More
Enrollment Complete in Phase 3 ASPEN Trial of Brensocatib in Adult Patients with Bronchiectasis; Topline Data Readout on Track for Second Quarter of 2024 Company to Provide Detailed Update on Early-Stage Research Programs on May 8 , 2023 Company on Track to Share Topline Data from Post-Marketing ARISE Study of ARIKAYCE ® (amikacin liposome inhalation suspension) in Third Quarter of 2023 ARIKAYCE Total Revenue of $65.2... Read More
The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More BRIDGEWATER, N.J. , April 24, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will host an investor and analyst event on Monday, May 8, 2023. The event, titled "The Future of Rare at... Read More
BRIDGEWATER, N.J. , April 20, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first quarter 2023 financial results on Thursday, May 4, 2023 . Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Thursday , May 4, 2023, to... Read More
BRIDGEWATER, N.J. , April 6, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 24 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each... Read More
Topline Data Remains on Track to be Reported in Q2 of 2024 More than 1,700 Adult Patients Enrolled in Global, Registrational Study of First-in-Class Treatment Candidate BRIDGEWATER, N.J. , March 31, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced that adult patient enrollment is complete as of... Read More
Data from Retrospective Study Evaluating the Association Between Hospitalization Burden and Delay in Diagnosis of Nontuberculous Mycobacterial (NTM) Lung Disease Among Patients with Chronic Obstructive Pulmonary Disease (COPD) to Be Shared in Oral Presentation Researchers to Present Subgroup Analysis from Phase 2 WILLOW Study Evaluating Brensocatib Treatment Outcomes by Disease Severity in Patients with Bronchiectasis... Read More
BRIDGEWATER, N.J. , March 3, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 17 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each... Read More
BRIDGEWATER, N.J. , March 1, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor conferences: The Cowen 43 rd Annual Healthcare Conference in Boston on Wednesday, March 8, 2023 , at 12:50 p.m. ET in a fireside chat The Barclays Global... Read More
Patient Screening Complete in Adult Patients in Phase 3 ASPEN Trial of Brensocatib in Bronchiectasis; Topline Data Readout on Track for Second Quarter of 2024 Company to Share Robust Updates Across Early-Stage Programs at Research Day on May 8 , 2023 Company on Track to Share Topline Data from Post-Marketing ARISE Study of ARIKAYCE ® (amikacin liposome inhalation suspension) in Third Quarter of 2023 ARIKAYCE Total Revenue of... Read More
BRIDGEWATER, N.J. , Feb. 9, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its fourth quarter and full year 2022 financial results on Thursday, February 23, 2023 . Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Thursday,... Read More
BRIDGEWATER, N.J. , Feb. 7, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 12:00 p.m. ET . The fireside chat will be webcast live and can be... Read More
BRIDGEWATER, N.J. , Feb. 3, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 18 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each... Read More
BRIDGEWATER, N.J. , Jan. 20, 2023 /PRNewswire/ - - Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 10 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each... Read More
Topline Data from Phase 2 PK/PD Study of Brensocatib in Patients with Cystic Fibrosis Show Clear Dose Response at all Evaluated Doses Treatment Discontinuation Rate of 15% Reported in Postmarketing ARISE Trial of ARIKAYCE ® (amikacin liposome inhalation suspension) in Frontline Patients with MAC Lung Disease Less than Half that of Pivotal Trial in Refractory Patients Blended, Blinded Event Rate Ranging from 1.12 to 1.15... Read More
BRIDGEWATER, N.J. , Jan. 3, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the 41 st Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 9, 2023 at 4:30 p.m. PT ( 7:30 p.m. ET ). The presentation and question and answer session... Read More
BRIDGEWATER, N.J. , Dec. 6, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 15 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each... Read More
BRIDGEWATER, N.J. , Nov. 30, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the Nasdaq 47 th Investor Conference in London on Wednesday, December 7 at 8:30 a.m. EST / 1:30 p.m. GMT . The fireside chat will be webcast live and can be accessed by visiting... Read More
Chimerix

COPYRIGHT ©2023 HEALTH STOCKS HUB